New RSV shot shows promise in protecting babies
NCT ID NCT07382219
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a single shot of nirsevimab (Beyfortus) can prevent RSV and other respiratory infections in infants under 1 year old. Researchers reviewed medical records from 816 babies at seven hospitals in China, comparing those who got the shot to those who did not. The goal was to see if the shot reduced hospitalizations for RSV and other respiratory illnesses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nirsevimab (Beyfortus), a monoclonal antibody given as a single shot
- What this could lead to
- If effective, nirsevimab could become a standard preventive option to protect infants from severe RSV infections during their first season.
- What could go wrong
- This is a retrospective study, not a randomized trial, so results may be influenced by unmeasured factors. Effectiveness may vary in different populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOWER RESPIRATORY TRACT INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Children's Hospital
Beijing, 100045, China
-
Beijing Luhe Hospital
Beijing, 101149, China
-
Inner Mongolia Maternity and Child Health Care Hospital
Hohhot, Inner Mongolia, 010000, China
-
Peking University Third Hospital
Beijing, 100191, China
-
Shenzhen Maternity & Child Healthcare Hospital
Shenzhen, 518000, China
-
Women and Children's Hospital
Qingdao, Shandong, 266000, China
-
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, 200092, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.